CA2531097C - Procede de preparation de produits formules de medicaments de regulation du metabolisme lipidique - Google Patents

Procede de preparation de produits formules de medicaments de regulation du metabolisme lipidique Download PDF

Info

Publication number
CA2531097C
CA2531097C CA2531097A CA2531097A CA2531097C CA 2531097 C CA2531097 C CA 2531097C CA 2531097 A CA2531097 A CA 2531097A CA 2531097 A CA2531097 A CA 2531097A CA 2531097 C CA2531097 C CA 2531097C
Authority
CA
Canada
Prior art keywords
admixture
drug
granulated
lipid
regulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2531097A
Other languages
English (en)
Other versions
CA2531097A1 (fr
Inventor
Yihong Qiu
Jacqueline Wardrop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CA2531097A1 publication Critical patent/CA2531097A1/fr
Application granted granted Critical
Publication of CA2531097C publication Critical patent/CA2531097C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2531097A 2003-07-02 2004-07-02 Procede de preparation de produits formules de medicaments de regulation du metabolisme lipidique Expired - Fee Related CA2531097C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61362203A 2003-07-02 2003-07-02
US10/613,622 2003-07-02
PCT/US2004/021361 WO2005002541A2 (fr) 2003-07-02 2004-07-02 Procede de preparation de produits formules de medicaments de regulation du metabolisme lipidique

Publications (2)

Publication Number Publication Date
CA2531097A1 CA2531097A1 (fr) 2005-01-13
CA2531097C true CA2531097C (fr) 2012-10-09

Family

ID=33564305

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2531097A Expired - Fee Related CA2531097C (fr) 2003-07-02 2004-07-02 Procede de preparation de produits formules de medicaments de regulation du metabolisme lipidique

Country Status (5)

Country Link
EP (1) EP1643975A2 (fr)
JP (2) JP5134818B2 (fr)
CA (1) CA2531097C (fr)
MX (1) MXPA06000111A (fr)
WO (1) WO2005002541A2 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494112B1 (fr) * 1980-11-19 1986-01-10 Laruelle Claude
JPH04103525A (ja) * 1990-08-22 1992-04-06 Sanwa Kagaku Kenkyusho Co Ltd 難水溶性薬物の持続性製剤化方法
DE4317127A1 (de) * 1993-05-19 1994-11-24 Merz & Co Gmbh & Co Verwendung von Etofibrat und pharmazeutische Zusammensetzungen, enthaltend Etofibrat, zur Behandlung der diabetischen Angio- und Retinopathie
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
US6383517B1 (en) * 1999-01-29 2002-05-07 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation

Also Published As

Publication number Publication date
JP2012149078A (ja) 2012-08-09
JP2007530415A (ja) 2007-11-01
JP5134818B2 (ja) 2013-01-30
EP1643975A2 (fr) 2006-04-12
MXPA06000111A (es) 2006-04-27
WO2005002541A2 (fr) 2005-01-13
CA2531097A1 (fr) 2005-01-13
WO2005002541A3 (fr) 2005-09-15

Similar Documents

Publication Publication Date Title
US6180138B1 (en) Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6465011B2 (en) Formulations comprising lipid-regulating agents
US4343789A (en) Sustained release pharmaceutical composition of solid medical material
US6383517B1 (en) Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
KR100766644B1 (ko) 페노피브레이트를 포함하는 약학적 조성물
US6368622B2 (en) Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US7976869B2 (en) Fenofibrate tablets
US20090292016A1 (en) Stable Pharmaceutical Compositions Containing Pravastatin
US8062664B2 (en) Process for preparing formulations of lipid-regulating drugs
US20100021393A1 (en) Pharmaceutical Compositions Comprising Effervescent Agents and Fenofibrate
CA2531097C (fr) Procede de preparation de produits formules de medicaments de regulation du metabolisme lipidique
US20060177512A1 (en) Process for preparing formulations of lipid-regulating drugs
WO2000072829A1 (fr) Formulations comprenant des agents regulateurs des lipides
US20080044468A1 (en) Processes For The Preparation Of Oral Dosage Formulations Of Modafinil
WO2010131265A1 (fr) Nouvelles compositions pharmaceutiques de fénofibrate de choline
KR20010015781A (ko) 속용성 의약 조성물
AU2002314915A1 (en) Stable pharmaceutical compositions containing pravastatin

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150702